Pharmacoeconomic studies on drug reimbursement policy of National Health Insurance

The amendment on Pharmaceutical Law 40-1 and 40-2 was announced in 2005. Drug regulation regarding to the pharmaceutical IPR and drug insurance policy need to be modified and implemented accordingly. This project tends to conduct a research on (1) pharmacoeconomic analysis of drug reimbursement policy based on the National Health Insurance Research Database in Taiwan; (2) the analysis of the rationality of drug reimbursement policy; and (3) the generation of a proposal for an IPR- and fairness-based drug reimbursement policy. This is a two year research. The aspects completed in the first year study includes (1) data analysis of drug reimbursement for the top 50 consumed medicines; (2) data analysis of drug reimbursement for the top 200 consumed medicines which counts for about 50% of total drug payment of the National Health Insurance; (3) propose the HPW model, a drug reimbursement equation by the principal investigator; (4) test the rationale of HPW model from the National Health Insurance Research Database ; (5) modify the parameters of HPW model and calculate and compare the outcome of drug payment; (6) calculate and compare the payment of National Health Insurance between drug under categories of IPR, generics and substitute generics. . The aspects covered in the second year will be (1) to calculate the difference between the current drug payment and the payment calculated base on the HPW model with different designated parameters;(2) to calculate the possible saving of total drug payment (i. e. the drug black hole) from the National Health Insurance; (3) to study and analyze the economic impact of drug payment policy with the respect of Pharmaceutical Law 40-1 and 40-2 regarding drug IPR. The anticipated results from this project will be the generation of a package of drug payment policy guarded by HPW model with optimized parameters which are feasible for DOH to implement year-by-year.

Project ID:PG9603-0335
External Project ID:DOH96-TD-D-113-004-(2/2)